Sun Yangqing, Liu Qingqing, Zhong Shangwei, Wei Rui, Luo Jun-Li
Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
The Cancer Research Institute and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Cancers (Basel). 2024 Jan 31;16(3):597. doi: 10.3390/cancers16030597.
FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, induces apoptosis of cancer cells, and increases the sensitivity of TNBC cells to T-cell-mediated cytotoxicity. Furthermore, the high expression of FTSJ1 in TNBC attenuates CD8+T cell infiltration in the tumor microenvironment (TME) correlated with poorer prognosis for clinical TNBC patients. In this study, we establish that FTSJ1 acts as a tumor promotor, is involved in cancer immune evasion, and may serve as a potential immunotherapy target in TNBC.
FtsJ RNA 2'-O-甲基转移酶1(FTSJ1)是甲基转移酶超家族的成员,参与核糖体RNA的加工和修饰。我们在此证明FTSJ1促进三阴性乳腺癌(TNBC)进展。敲低FTSJ1可抑制TNBC细胞增殖和发育,诱导癌细胞凋亡,并增加TNBC细胞对T细胞介导的细胞毒性的敏感性。此外,TNBC中FTSJ1的高表达减弱了肿瘤微环境(TME)中CD8 + T细胞浸润,这与临床TNBC患者的预后较差相关。在本研究中,我们确定FTSJ1作为肿瘤促进因子,参与癌症免疫逃逸,并可能作为TNBC潜在的免疫治疗靶点。